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Lipoprotein abnormalities as a risk factor for progressive non- proteinuria are well-documented as risk factors for the
diabetic renal disease. Renal disease is accompanied by charac- accelerated decline in renal function [1, 2]. Certain lipo-
teristic alterations of lipoprotein metabolism, which appear as protein abnormalities that appear during the course ofa consequence of nephrotic syndrome or renal insufficiency
renal insufficiency may also contribute to the progressionand are primarily reflected in an altered apolipoprotein profile
of disease [3–5].rather than elevated plasma lipid levels. Their full characteriza-
tion requires identification of discrete lipoprotein particles.
While nephrotic syndrome results in increased concentrations
of both cholesterol- and triglyceride-rich apoB-containing lipo- RENAL DYSLIPOPROTEINEMIA
proteins, renal insufficiency is characterized by an accumula-
Nephrotic syndrome and progressive renal failure aretion of intact or partially metabolised triglyceride-rich apoB-
accompanied by abnormalities of lipoprotein transport.containing lipoproteins. The dyslipidemia has been discussed as
a contributory factor for the progression of renal insufficiency While the nephrotic syndrome is characteristically asso-
through development of glomerulosclerosis and tubulointersti- ciated with elevated plasma lipid levels, the dyslipidemia
tial lesions together with accelerated atherosclerosis. of progressive renal insufficiency is predominantly re-Several experimental studies have shown that hyperlipid-
flected in altered concentrations and composition of indi-emia accelerates renal damage. Lipid-lowering treatment can
vidual lipoproteins [3, 6]. There are two major classesreduce renal lesions and preserve renal function. The documen-
tation in human nondiabetic progressive renal insufficiency is of circulating lipoproteins characterized and differenti-
more limited. We have found that increased concentrations ated on the basis of apolipoprotein (apo) composition,
of triglyceride-rich, but not cholesterol-rich, apoB-containing
one of which contains apoA-I and the other apoB aslipoproteins are, associated with a more rapid loss of renal
major protein constituents [7]. The apoA-I-containingfunction. The underlying pathophysiological mechanisms for
the relation between triglyceride-rich apoB-containing lipopro- lipoproteins occur in high density lipoprotein (HDL) and
teins and progression of renal insufficiency are not fully under- are considered to be anti-atherogenic, while atherogenic
stood. Treatment with hypolipemic drugs may attenuate the apoB-containing lipoproteins constitute the lipoproteins
renal dyslipidemia, but thus far there have been no reports
of very-low density lipoprotein (VLDL), intermediateabout controlled clinical trials testing the possible effect of
density lipoprotein (IDL) and LDL density ranges. Thesuch treatment on the progression of renal insufficiency. In
summary, there is evidence to suggest that some specific lipo- apoB-containing lipoproteins consist of lipoprotein B
protein abnormalities are a risk factor for the progression of (Lp-B) characterized by apoB as the sole protein constit-
renal dysfunction, but the final test of such assumptions still
uent and lipoprotein B:E (Lp-B:E), lipoprotein B:C (Lp-rests on the results of urgently needed controlled intervention
B:C), lipoprotein B:C:E (Lp-B:C:E) and lipoproteinstudies.
AII:B:C:D:E (Lp-A-II:B:C:D:E) which, in addition to
apoB, contain various amounts of minor apolipoproteins
such as apoA-II, apoC, apoD and apoE. The sum of Lp-Progression of renal insufficiency results from struc-
B:C, Lp-B:C:E and Lp-A-II:B:C:D:E is referred to astural changes in the glomeruli and the interstitial tissues,
lipoprotein B complex (Lp-Bc). While cholesterol estersand is related to the activity of the primary underlying
renal disease on one hand and to factors that may result are the main lipid component of Lp-B, the Lp-Bc parti-
from the renal disease or that may be primarily unrelated cles and Lp-B:E contain triglycerides as the major lipid
to the renal disease on the other [1]. Hypertension and constituent. The Lp-Bc includes intact and partially me-
tabolised lipoproteins with varying triglyceride content.
The nephrotic syndrome is characterized by increasedKey words: lipoproteins, progressive renal disease, renal failure, apoli-
poproteins, dyslipidemia. levels of both cholesterol-rich and triglyceride-rich apoB-
containing lipoproteins [6]. The main lipoprotein abnor- 1999 by the International Society of Nephrology
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mality of renal insufficiency is a progressive increase of
intact and partially delipidized triglyceride-rich apoB-
containing lipoproteins, Lp-Bc in IDL and LDL, with
smaller change in the levels of cholesterol-rich lipopro-
teins [3, 8, 9]. There is a progressive decline of apoA-
containing lipoproteins with reduced HDL cholesterol
levels. The dyslipidemia of renal insufficiency also in-
cludes compositional changes in the apoB-containing li-
poproteins with a relative enrichment of apoC-III [10].
Finally, lipoprotein(a) levels are frequently elevated in
patients with nephrotic syndrome or renal failure [3,
11]. The lipoprotein abnormalities are present in many
patients already at the early stages of renal function
impairment to become more accentuated in advancing Fig. 1. Rate of decline of renal function in relation to high and low
levels of apolipoprotein B (apoB)-containing lipoproteins in 44 patientsrenal failure [3, 10, 12].
with primary renal disease. LP-B denotes cholesterol-rich lipoprotein
B and LP-Bc triglyceride-rich lipoprotein Bc particles. Cutoff points:
median values, 110.0 and 13.5 mg/dl, respectively. (Reproduced withROLE OF LIPOPROTEINS IN MECHANISMS the permission of the Journal of the American Society of Nephrology.)
OF PROGRESSION
From experimental observations and findings of lipid
depositions in diseased kidneys, it has been suggested [18] observed a relationship between elevated concentra-
that circulating lipoproteins may be involved in the de- tions of plasma lipids or an altered relation between
velopment of glomerulosclerosis and tubulointerstitial apoA- and apoB-containing lipoproteins and the rate of
lesions that lead to a progressive loss of renal function progression. In the MDRD study, low HDL-cholesterol
[4, 13, 14]. After a primary insult the damaged glomerular was an independent risk factor for progression in the
barrier to the mesangium could allow an influx of macro- patient group with better renal function, which indirectly
molecules, such as lipoproteins. Through a series of events reflects that elevated triglycerides may contribute to pro-
analogous to the development of atherosclerosis, prolif- gression [2]. In a first study we showed significant correla-
tions between elevated levels of triglycerides, VLDLerative and sclerotic processes are triggered, ultimately
cholesterol and apoB, respectively, and the rate of pro-leading to a partial or complete obliteration of the glo-
gression of renal insufficiency in 34 patients during threemerular capillaries [15]. The glomerular lesions may also
years follow-up [20]. Based on these findings we carriedlead to a filtration of lipoproteins that may be taken up
out a three-year prospective study of 73 patients withand induce inflammatory and sclerotic processes in the
primary renal disease [21]. The decline of renal function,tubulointerstitial tissue [3, 4, 14].
measured with 51Cr-EDTA clearance was significantlyThe experimental evidence suggests that it is the ele-
associated with the baseline concentrations of apoB andvated concentration of apoB-containing lipoproteins that
LDL cholesterol. In the 43 patients with chronic glomer-contributes to further progression of renal injury [5, 13].
ulonephritis as the primary renal disease, also elevatedPharmacological reduction of both cholesterol-rich and
levels of triglycerides and apoE were significantly corre-triglyceride-rich apoB-containing lipoproteins attenuates
lated with a more rapid rate of progression. There was,the development of experimental glomerular and tubular
however, no correlation between baseline levels of lipo-
lesions [14]. It has been suggested that the composition protein(a) and the rate of decline of renal function [11].
of circulating lipoproteins may be a strong determinant These observations strongly suggested that one or
of their nephrotoxic potential and that structurally or more of the apoB-containing lipoproteins were risk fac-
functionally altered lipoprotein particles may exert a par- tors for the progressive loss of renal function. The devel-
ticularly damaging influence [16]. opment of specific sequential immunoaffinity chroma-
tography procedure has provided a tool for analysis of
the individual apoB-containing lipoproteins [7]. In ourLIPOPROTEINS AND PROGRESSION OF
prospective study we could then show that the associa-HUMAN RENAL DISEASE
tion between apoB-containing lipoproteins and the pro-
A number of studies have addressed the relationship gression of renal insufficiency was explained by increased
between dyslipidemia and progression of renal failure plasma concentrations of triglyceride-rich apoB-con-
in patients with renal disease. However, only a small taining lipoproteins (Lp-Bc) [9]. In contrast, the impact
number of studies have explored the dyslipidemia be- of elevated plasma concentrations of cholesterol-rich
yond measurements of plasma lipids [5, 9, 11, 17–21]. apoB-containing lipoproteins (Lp-B) was only marginal
(Fig. 1). These findings may appear to be in conflict withIn earlier studies Maschio et al [17] and Capelli et al
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the observed correlation between LDL-cholesterol and dysfunction, we need prospective controlled intervention
studies over a sufficiently long period of time. Awaitingthe rate of progression. However, LDL-cholesterol lev-
els, when estimated by the Friedewald formula, include those urgently needed studies, the approach to the dys-
lipidemia of patients with progressive renal disease mustthose of IDL cholesterol and the cholesterol content of
the majority of the complex apoB-containing lipoprotein be based on circumstantial evidence. They suggest that
treatment of the dyslipidemia, in addition to normaliza-particles.
While the above results lend strong support for an tion of blood pressure and reduction of proteinuria,
could provide additional means to retard the progressionassociation between levels of certain apoB-containing
lipoproteins and the rate of progression of renal disease, of chronic renal insufficiency.
they do not prove a causality. To this end, intervention
Reprint requests to Per-Ola Attman, M.D., Department of Nephrol-
studies, designed to show that the reduction of one or ogy, Sahlgrenska University Hospital, S-413 45 Go¨teborg, Sweden.
E-mail: per-ola.attman@sahlgrenska.semore of these lipoproteins also results in a slower rate
of progression, are needed but are not yet available.
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